Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration

Thomas M Hallam, Emanuela Gardenal, Fraser McBlane, GaEun Cho, Lucy Lee Ferraro, Eva Pekle, Darlene Lu, Kate Carney, Claire Wenden, Hannah Beadsmoore, Sergio Kaiser, Lauren Drage, Thomas Haye, Iris Kassem, Nalini Rangaswamy, Ma’en Obeidat, Cyndy Grosskreutz, Magali Saint-Geniez, David H Steel, Robert E MacLaren, Scott Ellis, Claire L Harris, Stephen Poor, Amy V Jones FOCUS Principal Investigators
doi: https://doi.org/10.1101/2024.06.12.24308796

Article Information

doi 
https://doi.org/10.1101/2024.06.12.24308796
History 
  • November 28, 2024.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Thomas M Hallam1,2,*,
  2. Emanuela Gardenal1,2,
  3. Fraser McBlane3,
  4. GaEun Cho4,
  5. Lucy Lee Ferraro5,
  6. Eva Pekle1,6,
  7. Darlene Lu7,
  8. Kate Carney1,8,
  9. Claire Wenden1,8,
  10. Hannah Beadsmoore1,8,
  11. Sergio Kaiser9,
  12. Lauren Drage1,10,
  13. Thomas Haye1,10,
  14. Iris Kassem11,
  15. Nalini Rangaswamy11,
  16. Ma’en Obeidat12,
  17. Cyndy Grosskreutz13,
  18. Magali Saint-Geniez13,
  19. David H Steel14,
  20. Robert E MacLaren15,
  21. FOCUS Principal Investigators,
  22. Scott Ellis1,2,
  23. Claire L Harris1,2,
  24. Stephen Poor4,* and
  25. Amy V Jones1,6,*
  1. 1Gyroscope Therapeutics Ltd, A Novartis Company, United Kingdom
  2. 2Translational Research, Ophthalmology, BioMedical Research, Novartis, United Kingdom
  3. 3Pharmacokinetic Sciences, Translational Medicine, BioMedical Research, Novartis, Switzerland
  4. 4Clinical Development, Global Drug Development, Novartis, United States
  5. 5Clinical Development, Global Drug Development, Novartis, Switzerland
  6. 6Biomarker Development, Translational Medicine, BioMedical Research, Novartis, United Kingdom
  7. 7Biostatistics, Global Drug Development, Novartis, United States
  8. 8Pharmacokinetic Sciences, Translational Medicine, BioMedical Research, Novartis, United Kingdom
  9. 9Biomarker Development, Translational Medicine, BioMedical Research, Novartis, Switzerland
  10. 10Cell and Gene Therapies, Technical Research and Development, Novartis, United Kingdom
  11. 11Ophthalmology, Translational Medicine, BioMedical Research, Novartis, United States
  12. 12Biomarker Development, Translational Medicine, BioMedical Research, Novartis, United States
  13. 13Translational Research, Ophthalmology, BioMedical Research, Novartis, United States
  14. 14Bioscience Institute, Newcastle University, Newcastle Upon Tyne, UK; Sunderland Eye Infirmary, Sunderland, United Kingdom
  15. 15Nuffield Laboratory of Ophthalmology and Oxford Eye Hospital, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  1. ↵*Corresponding authors. thomas.hallam{at}novartis.com
Back to top
Posted November 28, 2024.
Download PDF
Data/Code
Email
Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration
Thomas M Hallam, Emanuela Gardenal, Fraser McBlane, GaEun Cho, Lucy Lee Ferraro, Eva Pekle, Darlene Lu, Kate Carney, Claire Wenden, Hannah Beadsmoore, Sergio Kaiser, Lauren Drage, Thomas Haye, Iris Kassem, Nalini Rangaswamy, Ma’en Obeidat, Cyndy Grosskreutz, Magali Saint-Geniez, David H Steel, Robert E MacLaren, Scott Ellis, Claire L Harris, Stephen Poor, Amy V Jones
medRxiv 2024.06.12.24308796; doi: https://doi.org/10.1101/2024.06.12.24308796
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area